OCCIDENT invests in industrial biotech for the first time and participates as lead investor in Munich-based startup mk2 Biotechnologies, which focuses on the development and production of peptides.
With the multi-million seed funding, the company accelerates its further growth and aims for additional development milestones towards industrializing its new peptide production platform. This revolutionary, scalable synthesis technology platform enables the production of authentic peptides, regardless of their physical or chemical properties, at large scale and low cost.
More information can be found in the press release under the following Link.
More about mk2 Biotechnologies
